Navigation Links
Cell Therapeutics, Inc. (CTI) Shareholders Authorize Share Increase at Special Meeting of Shareholders
Date:1/28/2008

SEATTLE, Jan. 28 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTAX: CTIC) announced that in a special meeting today shareholders approved the proxy proposal amending and restating the Company's articles of incorporation to increase the number of authorized shares from 110 million to 210 million and to increase the number of authorized shares of common stock from 100 million to 200 million.

Louis A. Bianco, Chief Financial Officer at CTI, who chaired the meeting, said "The increase in the number of authorized shares of common stock provides CTI with flexibility needed to support the future growth of the business. I'd like to thank all of the shareholders who returned their proxies."

About Cell Therapeutics, Inc.

Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit http://www.cticseattle.com.

This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results. Specifically, the risks and uncertainties include risks related to the impact of the increase in authorized shares of stock and the future business growth of the Company as well as the risk factors listed or described from time to time in the Company's filings with the Securities and Exchange Commission including, without limitation, the Company's most recent filings on Forms 10-K, 8-K, and 10-Q. Except as may be required by law, CTI does not intend to (and expressly disclaims any such obligation to) update or alter its forward-looking statements whether as a result of new information, future events, or otherwise.

Media Contact:

Dan Eramian

T: 206.272.4343

C: 206.854.1200

Susan Callahan

T: 206.272.4472

F: 206.272.4434

E: media@ctiseattle.com

http://www.cticseattle.com/media.htm

Investors Contact:

Leah Grant

T: 206.282.7100

F: 206.272.4434

E: invest@ctiseattle.com

http://www.cticseattle.com/investors.htm


'/>"/>
SOURCE Cell Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Velcura Therapeutics, Inc. Can Begin Clinical Trials Following Successful Investigational New Drug Application to U.S. FDA
2. Cell Therapeutics, Inc. (CTI) Prices $1.27 million (euros 856.000) Offering of Common Stock through Societe Generale
3. Cell Therapeutics, Inc. Announces Authorization to Publish Italian Listing Prospectus
4. Cell Therapeutics, Inc. (CTI) Hosts Conference Call to Discuss Update on Zevalin(R) Acquisition, CMS Reimbursement, and PIX301 Timeline
5. Pearl Therapeutics, Inc. Expands Its Senior Management Team With Top Talent in Clinical Development and Regulatory Affairs
6. Cell Therapeutics, Inc. (CTI) to Submit Marketing Authorization Application for XYOTAX(TM) for First-line Non-small Cell Lung Cancer Ahead of Schedule
7. Cell Therapeutics, Inc. Announces Issuance of $23.25 Million in New Convertible Senior Notes in Exchange for $36.08 Million of Existing Convertible Senior Subordinated and Subordinated Notes
8. ARYx Therapeutics, Inc. Announces Pricing of its Initial Public Offering
9. Bioenergy Life Science and Integrative Therapeutics, Inc. Form Exclusive Co-Marketing Alliance
10. Velcura Therapeutics, Inc. Appoints Industry Executive to Lead Regulatory Affairs
11. Cell Therapeutics, Inc. (CTI) BIO Presentation to Be Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2017)... ... June 26, 2017 , ... NDA Partners ... Associate Director of Product Development R&D at Allergan and CMC expert with more ... start-up and established biopharma companies, has joined the firm as an Expert Consultant. ...
(Date:6/26/2017)... (PRWEB) , ... June 26, 2017 , ... Two new ... annual Shareholders Meeting on June 9, 2017: Jeremy Nowak, President, J Nowak Strategy and ... Center also announced the election of Glen N. Gaulton and Kenneth L. Kring, and ...
(Date:6/23/2017)... USA, and CARDIFF, UK (PRWEB) , ... June 23, 2017 , ... ... (LANL), and Brian Lula, president of Physik Instrumente USA, have been selected as this ... and photonics . , The two have been invited along with other honorees to ...
(Date:6/22/2017)... ... June 21, 2017 , ... Beaker, the industry’s pioneer ... the life sciences industry, today announces a strategic partnership with Alcami Corporation, a ... advantage of Beaker’s expertise in executive recruitment solutions, providing Alcami with access to ...
Breaking Biology Technology:
(Date:4/11/2017)... , Apr. 11, 2017 Research and Markets ... 2017-2021" report to their offering. ... The global eye tracking market to grow at a CAGR ... Global Eye Tracking Market 2017-2021, has been prepared based on an ... the market landscape and its growth prospects over the coming years. ...
(Date:4/5/2017)... -- Today HYPR Corp. , leading innovator in ... the HYPR platform is officially FIDO® Certified . ... that empowers biometric authentication across Fortune 500 enterprises and ... 15 million users across the financial services industry, however ... suites and physical access represent a growing portion of ...
(Date:3/30/2017)... The research team of The Hong Kong Polytechnic University ... adopting ground breaking 3D fingerprint minutiae recovery and matching technology, pushing ... for use in identification, crime investigation, immigration control, security of access ... ... A research team led by Dr Ajay ...
Breaking Biology News(10 mins):